Piramal Pharma Limited - Company Profile

Q: Who are the current directors of Piramal Pharma Limited?

The current directors of Piramal Pharma Limited are Nandini Ajay Piramal, Peter D Deyoung, Nathalie Ann Leitch, Vivek Valsaraj, Sridhar Gorthi, Jairaj Manohar Purandare, Tanya Smiley Dcosta, Peter Andrew Stevenson, Vibha Paul Rishi, Amit Jain, Ramadorai Subramanian.

It is a pharma public limited company based in Mumbai, Maharashtra, India, established in 2020.

2020 Mumbai, Maharashtra, India Active

Last Updated: December 30, 2025

Access Report

About Piramal Pharma Limited

Piramal Pharma Limited, a active public limited company, was established on 04 March 2020 in Mumbai, Maharashtra, India. Engaging in drug formulation & development within the manufacturing sector, it holds CIN: L24297MH2020PLC338592. Registered under ROC Roc Mumbai. it is listed on BSE: 543635. It has an authorized capital of ₹3,000.00 Cr and a paid-up capital of ₹1,329.25 Cr.

It upholds a compliant status. In 2023, it reported revenue of ₹3,784.29 Cr and a net worth of ₹5,261.79 Cr. Employing 3,851 professional, Its leadership includes Nandini Ajay Piramal (Whole-Time Director), Peter D Deyoung (Whole-Time Director), Nathalie Ann Leitch (Director). Past directors included Nandini Ajay Piramal, Peter D Deyoung, Neeraj Bharadwaj. It holds ₹2,430.00 Cr open charges and ₹1,000.00 Cr settled loans. Its latest AGM occurred on 30 July 2025, with the balance sheet filed on 31 March 2025. It is based at Gr. Flr., Piramal Ananta, Agastya Corp. Park, Kamani Junction, Lbs Marg, Kurla, Mumbai, Maharashtra, 400070.

Company Details

CIN/LLPIN
L24297MH2020PLC338592
Registration Number
338592
Incorporation Date
04 March 2020
Authorized Capital
₹3,000.00 Cr
Paid-Up Capital
₹1,329.25 Cr
ROC Code
Roc Mumbai
Listing Status
Listed (BSE: 543635)
Company Status
Active

Key Metrics

Authorised Capital ₹ 3,000.00 Cr as on 30-12-2025
Paid Up Capital ₹ 1,329.25 Cr as on 30-12-2025
Company Age 5 Year, 11 Months
Last Filing with ROC 31 Mar 2025
Open Charges ₹ 2,430.00 Cr as on 30-12-2025
Satisfied Charges ₹ 1,000.00 Cr as on 30-12-2025
Revenue Growth **** 14.03% (FY 2023)
Profit Growth **** -79.74% (FY 2023)
Ebitda **** -75.45% (FY 2023)
Net Worth 3.84% (FY 2023)
Total Assets **** 11.57% (FY 2023)

Comprehensive Company Insights

Explore comprehensive insights into Piramal Pharma Limited — covering financial performance, compliance records, Competitor, shareholding patterns, directors, key metrics, and litigation history. Unlock to see detailed insights and stay informed.

Access Report

Who are the key members and board of directors at Piramal Pharma Limited?

Current Directors

Name	Designation	Appointment Date	Status
Nandini Ajay Piramal	Whole-Time Director	04 Mar 2020	Current
Peter D Deyoung	Whole-Time Director	04 Mar 2020	Current
Nathalie Ann Leitch	Director	28 Jan 2025	Current
Sridhar Gorthi	Director	30 Mar 2022	Current
Jairaj Manohar Purandare	Director	09 Feb 2021	Current
Peter Andrew Stevenson	Director	30 Mar 2022	Current

Past Directors

Name	Designation	Cessation	Status
Pramod Abcsdd	Director	01 Apr 2021	Past
Pramod Abcsdd	Director	06 Oct 2020	Past
Pramod Abcsdd	Director	14 May 2025	Past
Pramod Abcsdd	Additional Director	28 Jul 2022	Past
Pramod Abcsdd	Additional Director	28 Jul 2022	Past
Pramod Abcsdd	Director	08 Feb 2022	Past

Discover detailed profiles of directors and KMP - Unlock leadership insights today!

Financial Performance of Piramal Pharma.

Piramal Pharma Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 14.03% increase. The company also saw a substantial fall in profitability, with a 79.74% decrease in profit. The company's net worth moved up by a moderate rise of 3.84%.

Date	Amount	Transaction Name	Valuation	Lead Investors	Investors
Jul, 2021	Amount	Post-IPO - Grab	Valuation	investors	Emtek
Feb, 2021	Amount	Post-IPO - Grab	Valuation	investors	Signite Partners
Jan, 2021	Amount	Post-IPO - Grab	Valuation	investors	Hana Financial Group , GGV Capital
Feb, 2021	Amount	Post-IPO - Grab	Valuation	investors	Signite Partners

Upgrade Required

Full access to Financial is available only for users with an active Premium plan.

Key Matrics
Balance Sheet
Profit and Loss
Cash Flow
Ratios

Metrics

(FY 2023)

YOY Growth

(FY 2022)

(FY 2021)

(FY 2020)

(FY 2019)

Total Revenue

********

14.03%

*******

Revenue from Operations

*******

11.25%

*******

Total Assets

*******

11.57%

*******

Profit or Loss

*******

-79.74%

*******

Net Worth

*******

3.84%

*******

EBITDA

*******

-75.45%

*******

Discover detailed financial data and - Unlock financial today!

What is the Ownership and Shareholding Structure of Piramal Pharma?

In 2023, Piramal Pharma had a promoter holding of 34.79% and a public holding of 65.22%. The company had 1 Subsidiary and 2 Associate Companies. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.

Shareholding Pattern (FY 2024)

Promoters: 92.83%
Public: 4.10%
Others: 3.07%

Shareholding Pattern over the Year

	FY (2024)	FY (2023)	FY (2022)	FY (2021)	FY (2020)
Promoters	92.83	94.62	94.55	94.55	94.55
Public	4.10	3.89	3.95	3.96	3.98
Others	3.07	1.49	1.50	1.49	1.47

Upgrade Required

Full access to Ownership and Shareholding Structure is available only for users with an active Premium plan.

Reveal ownership structures and financial performance - Get instant access now!

Charges (Loans)

Open Charges

₹24,300,000,000.00

Satisfied Charges

₹10,000,000,000.00

Charges Breakdown by Lending Institutions

Idbi Trusteeship Services Limited : 1580.00 Cr
Others : 450.00 Cr
The Hongkong And Shanghai Banking Corporation Limited : 300.00 Cr
Standard Chartered Bank : 50.00 Cr
Citi Bank N.A. : 50.00 Cr

Latest Charge Details

Date	Lender	Amount	Status
19 May 2025	Idbi Trusteeship Services Limited	₹300.00 Cr	Open
12 Dec 2024	Idbi Trusteeship Services Limited	₹100.00 Cr	Open
10 Dec 2024	Idbi Trusteeship Services Limited	₹200.00 Cr	Open
10 Dec 2024	Idbi Trusteeship Services Limited	₹100.00 Cr	Open
10 Sep 2024	Idbi Trusteeship Services Limited	₹150.00 Cr	Open

Explore comprehensive loan charge details -

How Many Employees Work at Piramal Pharma?

Piramal Pharma has a workforce of 3851 employees as of Apr 02, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.

Employee Date	Number of Employees
2020	78,000
2021	80,500
2022	83,200
2023	86,000
2024	89,500
2025	92,000

Upgrade Required

Full access to People is available only for users with an active Premium plan.

Deals i

Gain comprehensive insights into the Deals and Valuation data of Piramal Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Piramal Pharma's trajectory.

Rating

Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.

Alerts

Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.

Explore deal ratings and alerts - Get instant access now!

Latest Updates, News, and FAQs on Piramal Pharma

Recent Activity within the Organization

Annual General Meeting

Progress on Piramal Pharma Limited last Annual general meeting of members was held on 30 Jul 2025 as per latest MCA records. was documented.
30 Jul 2025
Charges

A charge with Idbi Trusteeship Services Limited amounted to Rs. 300.00 Cr with Charge ID 101100712 was registered on 19 May 2025. was recorded as a recent event.
19 May 2025
Director Appointment

The activity Amit Jain was appointed as a Director was appointed as a Director on 14 May 2025 & has been associated with this company since 9 months . was completed.
14 May 2025
Balance Sheet

Progress on Piramal Pharma Limited has filed its annual Financial statements for the year ended 31 Mar 2025 with Roc Mumbai. was documented.
31 Mar 2025
Director Appointment

Progress on Nathalie Ann Leitch was appointed as a Director was appointed as a Director on 28 Jan 2025 & has been associated with this company since 1 year 14 days . was documented.
28 Jan 2025
Charges

Progress on A charge with Idbi Trusteeship Services Limited amounted to Rs. 100.00 Cr with Charge ID 101026540 was registered on 12 Dec 2024. was documented.
12 Dec 2024

Explore recent activity and updates - View Recent Activity